bioAffinity Technologies, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from bioAffinity Technologies, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: $3 per $100 of sales comes from others' credit, against $6,850 from others' credit three years earlier. Less money tied up than 92% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.3 times its market value (net cash). Higher than 92% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 1,510% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 91% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-139.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 85% of Healthcare companies in United States.
Cash Locked Ratio
−$3Money owed to suppliers is larger than money owed by customers plus stock: $3 per $100 of sales comes from others' credit, against $6,850 from others' credit three years earlier.
Less money tied up than 92% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
−$111Sales grew 127,070% in 3 years, but profit fell: $111 less profit per $100 of extra sales.
Lower than 87% of Healthcare companies in United States.
Asset Productivity Ratio
+127070% / -10%In 3 years sales changed by +127070% while total assets changed by -10%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-88.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 81% of Healthcare companies in United States.
Cash Cushion Ratio
1.3× cashCash, after subtracting all debt, is 1.3 times its market value (net cash).
Higher than 92% of Healthcare companies in United States.
Tangible Assets Ratio
81%Of every $100 the company owns, $81 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 50% of Healthcare companies in United States.
Tangible Net Worth Ratio
71%Of every $100 of net worth, $71 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 57% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
bioAffinity Technologies, Inc. made a loss over the last year. bioAffinity Technologies, Inc. owes $0.51 for every $1 it owns. bioAffinity Technologies, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossbioAffinity Technologies, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.08The share price is 1.08 times bioAffinity Technologies, Inc.'s book value per share, lower than 77% of Healthcare companies in United States.
Market cap
$4 MThe total market value of all of bioAffinity Technologies, Inc.'s shares at today's price (share price × number of shares), smaller than 95% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$4 MWhat bioAffinity Technologies, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.94Net worth divided by the number of shares. The share price of $3.17 is 1.1 times this, which is the P/B above.
Return on equity (ROE)
-1860.2%bioAffinity Technologies, Inc. lost 1860.2% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
Owes vs Owns
0.51×bioAffinity Technologies, Inc. owes $0.51 for every $1 it owns (moderate), higher than 56% of Healthcare companies in United States.
Dividend yield
NonebioAffinity Technologies, Inc. does not currently pay a dividend.
Revenue growth
-35%Revenue fell 35% in the year to Dec 2025, and grew 983% a year on average over 3 years.
Profit growth
LossbioAffinity Technologies, Inc. made a loss in each of the last two years.
Profit margin
-244.1%bioAffinity Technologies, Inc. lost $244 for every $100 of revenue.
Interest cover
Not coveredbioAffinity Technologies, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashbioAffinity Technologies, Inc. held $5 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For bioAffinity Technologies, Inc.: $4 M ÷ $4 M (30 Jun 2026) = 1.1.
What is bioAffinity Technologies, Inc.'s return on equity?
bioAffinity Technologies, Inc. lost 1860.2% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
How much does bioAffinity Technologies, Inc. owe compared with what it owns?
bioAffinity Technologies, Inc. owes $0.51 for every $1 it owns (moderate), higher than 56% of Healthcare companies in United States.
Does bioAffinity Technologies, Inc. pay a dividend?
No. bioAffinity Technologies, Inc. does not currently pay a dividend.
Is bioAffinity Technologies, Inc.'s revenue growing?
Revenue fell 35% in the year to Dec 2025, and grew 983% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.